Full Editor

Bioverativ Inc. (BIVV)

Followers
1
Posters
3
Posts (Today)
0
Posts (Total)
5
Created
04/05/17
Type
Free
Moderators
About Bioverativ Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter. Bioverativ Inc. MEDIA CONTACT: Tracy Vineis, +1 781-663-4350 media@bioverativ.com or INVESTOR CONTACT: Susan Altschuller, +1 781-663-4360 IR@bioverativ.com
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
BIVV Latest News
  • No Recent News Available for this company!
Most Liked Posts
(Last 30 Days)
New Post